An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer.

ABSTRACT:

Objective

To establish a combined radiomics-clinical model for the early prediction of a prostate-specific antigen(PSA) response in patients with metastatic castration-resistant prostate cancer(mCRPC) after treatment with abiraterone acetate(AA).

Methods

The data of a total of 60 mCRPC patients from two hospitals were retrospectively analyzed and randomized into a training group(n=48) or a validation group(n=12). By extracting features from biparametric MRI, including T2-weighted imaging(T2WI), diffusion-weighted imaging(DWI), and apparent diffusion coefficient(ADC) maps, radiomics features from the training dataset were selected using least absolute shrinkage and selection operator(LASSO) regression. Four predictive models were developed to assess the efficacy of abirateron

SUBMITTER: Wu Y 

PROVIDER: S-EPMC11807802 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature